Henry E. Pelish, Chief Scientific Officer at Nuvalent, Inc. (NUVL), sold 19,740 shares at $86.11 ($1.8M) on 2025-10-14, disclosed to the SEC on 2025-10-15.
Scheduled sale ($1.8M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $89.81 | 7,637 | $686K | 39.1% |
| 2 | $89.81 | 7,637 | $686K | 39.1% |
| 3 | $84.98 | 1,167 | $99K | 5.7% |
| 4 | $84.98 | 1,167 | $99K | 5.7% |
| 5 | $86.11 | 866 | $75K | 4.3% |
| 6 | $86.11 | 866 |
| $75K |
| 4.3% |
| 7 | $87.39 | 400 | $35K | 2.0% |
| Total | $88.87 avg | 19,740 | $1.8M | 100% |
| Filing → |
| NUVL | SELL | 2026-03-16 | $3.4M | — | Filing → |
| NUVL | SELL | 2026-01-07 | $502K | — | Filing → |
| NUVL | SELL | 2025-10-17 | $2.6M | — | Filing → |